Interventional Systems, an Australian robotics firm, has gained clearance from the US Food and Drug Administration (FDA) to sell its Micromate robot in the US commercially. Micromate, a needle-based intervention robot, will be used for percutaneous procedures using CT optical navigation, including biopsies, ablations, and other procedures to assess and treat conditions in the chest, abdomen, and musculoskeletal structures. The clearance follows the robot’s successful application in Europe at the Netherlands-based St Antonius Hospital. It heads to the US, where its use has been limited since 2021 to percutaneous needle interventions performed under live imaging. The company aims to provide a cost-effective, precise, and efficient solution to meet the increasing demands of the healthcare sector.
To read more, click here.
[Source: Medical Device Network, October 20th, 2023]